← Back

Tsubota Laboratory Incorporated

Tsubota Laboratory Incorporated engages in the development and sale of pharmaceuticals and medical devices for the treatment of myopia, dry eyes, presbyopia, and neurological disorders. The company was incorporated in 2012 and is based in Tokyo, Japan.

Price · split & dividend adjusted
News & notes moving 4890.JP
4890.JP

Mitsui Matsushima Holdings raises earnings forecast and dividend, makes Sanyo a subsidiary

Mitsui Matsushima Holdings has revised upward its consolidated earnings forecast for the fiscal year ending March 2027 and announced an increase in its annual dividend. At the same time, it will make Sanyo, a manufacturer and seller of cotton swabs and cotton balls, a subsidiary. Separately, OBC reported a sharp profit increase for the first quarter of the fiscal year ending March 2027, while CDS and Toho Remac revised downward their consolidated earnings forecasts for the cumulative second quarter of the fiscal year ending December 2026. Bronco Billy announced its financial results and revised its earnings and dividend forecasts, and Stemrim reported that a patent for its regenerative medicine Redasemtide related to cartilage disease has been registered in Mexico. Tsubota Laboratory achieved a milestone upon submission of the clinical study report for TLG-001, confirming receipt of payment, Mitra established a wholly owned subsidiary specializing in inheritance-related services, and AZC Maruwa introduced a new shareholder benefit program.
ウエルスアドバイザー·35dRead more ▾